Ovarian steroid hormones and anti-estrogens: Risks for and prevention of cancers of the breast and endometrium in the menopause;Ovarielle steroidhormone und anti-ostrogene: Risiken zu und pravention in der karzinogenese der mamma und des endometriums in der postmenopause

Geburtshilfe und Frauenheilkunde

Volumn 60, Issue 2, 2000, Pages 77-85

  Beckmann, M W ^a   Jap, D ^a   Kuschel, B ^a   Dall, P ^a   Lux, M P ^a   Hanstein, B ^a   Bender, H G ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; DRUG EFFECT; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HORMONE RECEPTOR INTERACTION; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; REVIEW;

EID: 0034004038     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Armstrong BK. Oestrogen therapy after the menopause-Boon or bane? Med J Austr 1988; 148: 213-214
2. Beckmann MW, Kuschel B, Bender HC. Ovarialkarzinom: Epidemiologie, Genetik und Prävention. In: Jänicke F, Thommsen C (Hrsg). Educational book: Ovarialkarzinom-State of the art. Heidelberg: Springer Verlag, 2000; in press
3. Beckmann MW, Mohrmann T, Kuschel B, Dall P, Schnürch HG. Hormonersatztherapie (HRT) nach Mammakarzinomerkrankung - Ergebnisse einer Beobachtungsstudie. Geb Frau 1998; 58: 193-196
4. Beckmann MW, Mohrmann T, Niederacher D. Wirkungsmechanismen von Steroidhormone und Steroidhormon-Antagonisten und ihre Bedeutung für die Tumorkarzinogenese. Gynäkologe 1997; 30: 617-623
5. Beckmann MW, Niederacher D, Schnürch HG, Gusterson BA, Bender HG. Hochrisikofamilien mit Mamma- und Ovarialkarzinomen: Möglichkeiten der Beratung, genetischen Analyse und Früherkennung. Deutsches Ärzteblatt 1997; 94: A161-167
6. Beckmann MW, Niederacher D, Schnürch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumor heterogeneity. J Molecular Medicine 1997; 75: 429-439
7. Beckmann MW. Bedeutung der Steroidhormonen für die Entstehung und Progression von malignen Brustdrüsenveränderungen im Klimakterium und der Postmenopause. J Menopause 1997; 3: 24-29
8. Beckmann MW, Hanstein B, Niederacher D, Jap D, Kuschel B, Bender HG. Wirkmechanismen ovarieller Steroidhormone und Anti-Östrogene in der Karzinogenese der Mamma und des Endometriums. Geh Fra 1999; 60: 1-6
9. Beckmann MW, Untch M, Rabe T, Schulz KD, Bender HG. Prävention des Mammakarzinoms. Gynäkologe 1999; 32: 150-157
10. Belchetz PE. Hormonal treatment of postmenopausal women. N Eng J Med 1994; 330: 1062-1071
11. Berkqvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to oestrogen and oestrogen-progesteron replacement therapy. Am J Epidem 1992; 130: 221-228
12. Bissett D, Davis JA, George WD. Gynaecological monitoring during tamoxifen therapy. Lancet 1994; 344: 1244
13. Bluming AZ. Hormone replacement therapy: Benefits and risk for the general postmenopausal female population and for women with a history of previously treated breast cancer. Semin Oncol 1993; 20: 662-674
14. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obst Gynecol 1995; 85: 11-17
15. Bryant GW. Administration of estrogens to patients with previous diagnosis of endometrial adenocarcinoma. South Med J 1990; 83: 725-726
16. Chapman JA, Di Saia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996; 175: 1195-1200
17. Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tommey DC, Wood WC. Estrogen replacement therapy in breast cancer survivors: A time for change. JAMA 1994; 272: 540-
18. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-1593
19. Colditz GA, Rosner BA, Speizer FE. Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 1996; 88: 365-370
20. Collaborative Group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350: 1047-1059
21. Colton T, Greenberg R, Noller K, Ressseguie L, Van Bennekom C, Heeren T, Zhang Y. Breast cancer in mothers prescribed diethylstilbestrol in pregnancy. JAMA 1993; 269: 2096-2100
22. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, Daling JR. Population-based study tamoxifen therapy and subsequent ovarian, endometrial, and breast cancer. J Natl Cancer Inst 1995; 87: 1359-1364
23. Creasman WT. Estrogen replacement therapy: is previously treated cancer a contraindication? Obstet Gynecol 1991; 77: 709-717
24. Cuenca RE, Giachino J, Arredondo MA, Hempling R, Edge SB. Endometrial carcinoma associated with breast carcinoma. Cancer 1996; 77: 2058-2063
25. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281: 2189-2197
26. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF. Second cancers after adjuvant therapy for breast cancer. J Natl Cancer Inst 1996; 88: 832-834
27. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ. Effects of Raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-1647
28. Devilee P, Cornelisse CJ. Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1994; 1198: 113-130
29. Dhodapkar MV, Ingle JN, Ahmann DL. Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 1995; 75: 43-46
30. Di Saia PJ, Grose EA, Kurosaki T, Gildea M, Cowan B, Anton-Culver H. Hormone replacement therapy in breast cancer survivors: A cohort study. Am J Obstet Gynecol 1996; 147: 1494-1498
31. Di Saia PJ, Odicino F, Grosen EA, Cowan B, Peconelli S, While AG. Hormone replacement therapy in breast cancer. Lancet 1993; 342: 1232
32. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Int Med 1991; 151: 67-72
33. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: overview of the randomised trials. Lancet 1998; 351: 1451-1467
34. Eden JA, Bush T, Nand S, Wren BG. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995; 2: 67-72
35. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer rik in Denmark. Int J Cancer 1988; 42: 832-838
36. Fischer B, Costantino JP, Wickerham DL, and other National Surgical Adjuvant Breast and Bowel Project Investigators . Tamoxifen for prevention of breast cancer: report of the National surgical adjuvant breast and powel project P-1 study. J Natl Cancer Inst 1998; 90: 1371-1388
37. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology. JAMA 1999; 281: 2091-2097
38. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998; 90: 1601-1608
39. Grady D, Gebretsadik T, Kerlikowski K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a metaanalysis. Obstet Gynecol 1995; 85: 304-313
40. Grodstein F, Stamper MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-1775
41. Hanstein B, Bender HG. Molekularbiologie des Östrogenrezeptors und seine Regulation durch Östrogene und Antiöstrogene. Gynäkologe 1998; 31: 1046-1050
42. Jones C, Ingram D, Mattes E, Hahnel R. The effect of hormone replacement therapy on prognostic indices in women with breast cancer. Med J Austral 1994; 161: 106-110
43. Kuhl H, Runnebaum B, Schneider HPG. Langfristige Hormonsubstitution und Mammakarzinomrisiko: aktuelle Bestandsaufnahme. Der Frauenarzt 1995; 36: 1117-1124
44. Kuschel B, Aba F, Lux M, Jap D, Bender HG, Beckmann MW. Ermittlung des individuellen Erkrankungsrisikos und der Möglichkeiten zur Prävention. Zeitschrift für ärztliche Fortbildung und Qualitätssicherung (ZaeFQ) 2000; in press
45. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990; 36: 189-191
46. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999; 81: 339-344
47. Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, Bogdan G, Willett WC. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidmiol 1995; 142: 788-795
48. Rabe T, Vlasecu E, Heinemann L, von Holst T. Endometriumkarzinom. Onkologe 1999; 5: 432-443
49. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-1618
50. Paech K, Webb P, Kuiper GGJM. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997; 277: 1508-1510
51. Persson I, Yuen J, Bergkvist L, Schaurer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a swedish cohort. Int J Cancer 1996; 67: 327-332
52. Powels TJ, Hickish T, Casey S, O'Brien M. Hormone replacement after breast cancer. Lancet 1993; 342: 60-61
53. Powels T, Eeles R, Ashely S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98-101
54. Prentice RL. Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancer. Prev Med 1991; 20: 38-46
55. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 1998; 16: 2018-2024
56. Rinehart CA, Xu L, Van Le L, Kaufman DG. Diethylstilbestrol-induced immortalization of human endometrial cells: alterations in p53 and estrogen receptor. Mol Carcinogenesis 1996; 15: 115-123
57. Roy JA, Sawka CA, Pritchard KI. Hormone replacement therapy in women with breast cancer: Do the risks outweight the benefits? J Clin Oncol 1996; 14: 997-1006
58. Schnürch HG, Lopens A, Diedrich K. Mehrschrittkarzinogenese als Modell der Tumorentwicklung. Gynäkologe 1998; 31: 1933-1038
59. Schwartz LB, Krey L, Demopoulos R, Goldstein SR, Nachtigall LE, Mittal K. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. AmJ Obstet Gynecol 1997; 176: 129-137
60. Seeley T. Östrogen replacement therapy after hysterectomy. Br MedJ 1992; 305: 811-812
61. Sellers TA, Kushi LH, Potter JD, Kaye SA, Nelson CL, McGovern PG, Folsom AR. Effect of family history, body fat distribution and reproductive factors on the risk of breast cancer in premenopausal women. N Eng J Med 1992; 326: 1323-1329
62. Silero-Arenas M, Delgado-Rodriguez M, Rodrigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta analysis. Obstet Gynecol 1992; 79: 286-294
63. Smith DC, Prentice R, Thompson DC, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293: 1164-1167
64. Sourander L, Rajala T, Räihä I, Makinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998; 352: 1965-1969
65. Standford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274: 137-142
66. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL. A Meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985-1990
67. Stoll BA. Hormone replacement therapy in women treated with breast cancer. Eur J Cancer Clin Oncol 1989; 25: 1909-1913
68. The writing group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin intervention (PEPI) trial. JAMA 1996; 5: 370-375
69. Van Leeuwen FE, Rookus MA. The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer. EurJ Cancer Clin Oncol 1989; 25: 1961-1972
70. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93-97
71. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, Van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274-277
72. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993; 165: 372-375
73. Wu AH, Pike MC, Stram DO. Metaanlysis: diatary fat intake, serum estrogen levels and risk of breast cancer. J Natl Institute Health 1999; 91: 529-534